Rebekka Schneider Group

Rebekka Schneider

Oncode Investigator at Erasmus MC

My Research

Rebekka Schneider is a pathologist by training with a strong background in clinical hematopathology and basic research. She performed her postdoctoral fellowship in Ben Ebert‘s lab at Harvard Medical School, Brigham and Women’s Hospital, Boston, USA. In her own lab in the department of Hematology at Erasmus MC (Rotterdam), her primary focus is disease-oriented laboratory investigation of clonal myeloid neoplasms, employing a range of genomic technologies as well as classical cellular and molecular biology experimental approaches.

She discovered as the first recurrent mutations in a blood cancer called del(5q) MDS. She identified the “Achilles Heel” of the mutated cells which can be used to specifically eliminate these disease-causing cells without affecting normal blood formation – one of the main challenges in cancer research (Schneider et al. Cancer Cell 2014). She further identified that inflammation and activation of the immune system are central mechanisms in the development of a group of blood cancer called myelodysplastic syndrome. Using CRISPR/Cas9-gene editing, she demonstrated that targeting inflammation-inducing „alarmins“ can restore the normal function of diseased hematopoietic cells (Schneider et al. Nature Medicine 2016) – a novel strategy in the treatment. Another major achievement of her laboratory has been the identification of fibrosis-driving cells in an incurable blood cancer called primary myelofibrosis (PMF); (Schneider et al. Cell Stem Cell 2017). She identified new concepts in the diagnosis and treatment of PMF, which are of significant translational value. She received a Starting Grant by the European Research Commission (ERC) to continue this line of research.

Her research studies have been considered milestones in the understanding of precursor lesions of blood cancer, were voted as “best in hematology” 2014 by the American Society of Hematology, she was honored with the Tito Bastianello MDS award 2015, the Innovation Award of German Academic Medicine 2016, the Arthur Pappenheim award of the German Society of Hematology 2016, the Johann Georg Zimmermann Award 2017 (European Cancer Research) and the Swammerdam award 2019 of the Dutch Society for Hematology.


  • 2019: Swammerdam Award Nederlandse Vereniging voor Hematologie (Dutch Hematology Association)
  • 2017: ERC Starting Grant; deFIBER; Dissecting the cellular and molecular dynamics of bone marrow fibrosis for improved diagnostics and treatment
  • 2017: EMC fellowship; Functional and molecular dissection of the clonal selection in myeloproliferative neoplasms
  • 2017: International MPN foundation; Dissecting the cellular and molecular dynamics of bone marrow fibrosis for improved diagnostics and treatment
  • 2018: KWF Bas Mulder Award; Dissecting the mechanisms of malignant transformation in del(5q) myelodysplastic syndrome to selectively target the disease-initiating hematopoietic stem cells
  • 2017: European Hematology Association (EHA), John Goldman Clinical Research grant; Functional dissection of abnormal protein translation in the erythroid differentiation defect in del(5q) MDS
  • 2017: Johann Georg Zimmermann Award for Excellence in Cancer Research
  • 2016 Innovation Award German Academic Medicine (Innovationspreis Deutsche Hochschulmedizin)
  • 2016: Artur Pappenheim Award, Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO; German Society for Hematology and Oncology)

Key Publications

  1. Ribezzo, Leisten…and Schneider. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome. Leukemia 2019; PMID 30651631
  2. Schneider et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nature Medicine 2016; PMID 26878232
  3. Schneider et al. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell2017; PMID: 28457748
  4. Schneider et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 2014; PMID: 25242043
  5. Krönke...Schneider et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 2015; PMID 26131937
Contact Information
Rebekka Schneider Oncode Investigator

More Research

Research Strategy
Focus and Approach
Over 800 scientists working under a single strategy. Oncode is all about uniting efforts and bringing focus to research.
Support Programme
Our supporting programmes
New plans that help fulfil Oncode's objectives get our full support. Young talents are matched with mentors on the basis of their personal endeavours.
Research Groups
Our Groups
We firmly believe in sharing knowledge. From experienced veterans to talented young researchers, we work together in 61 groups.